3 Articles
3 Articles
All
Left
1
Center
Right
Chicago – The dual neurokinin antagonist elinzanetant has shown relief of vasomotor symptoms in a Phase 3 study in patients who received endocrine therapy after the removal of estrogen receptor-positive breast cancer. The manufacturer announced this in a press release in January. Detailed...
Women's Hospital Director Prof. Marion Kiechle: "The non-treatment of menopause complaints costs the German economy 9.4 billion euros each year
Coverage Details
Total News Sources3
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage